The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study examines the effectiveness and tolerability of stimulants in children with attention-deficit/hyperactivity disorder (ADHD) and disruptive mood dysregulation disorder (DMDD). METHODS: To be eligible, participants had to meet Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV) criteria for the combined subtype of ADHD and National Institute of Mental Health (NIMH) severe mood dysregulation criteria. The Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-V) DMDD criteria were retrospectively assessed after the study was completed. An open-label medication trial lasting up to 6 weeks was completed to optimize the central nervous system (CNS) stimulant dose. Measures of affective symptoms, ADHD symptoms and other disruptive behaviors, impairment, and structured side effect ratings were collected before and after the medication trial. RESULTS: Optimization of stimulant medication was associated with a significant decline in depressive symptoms on the Childhood Depression Rating Score-Revised Scale (p<0.05, Cohen's d=0.61) and Mood Severity Index score (p<0.05, Cohen's d=0.55), but not in manic-like symptoms on the Young Mania Rating Scale. There was a significant reduction in ADHD (p<0.05, Cohen's d=0.95), oppositional defiant disorder (ODD) (p<0.05, Cohen's d=0.5), and conduct disorder (CD) symptoms (p<0.05, Cohen's d=0.65) as rated by parents. There was also a significant reduction in teacher-rated ADHD (p<0.05, Cohen's d=0.33) but not in ODD symptoms. Medications were well tolerated and there was no increase in side effect ratings seen with dose optimization. Significant improvement in functioning was reported by clinicians and parents (all p's<0.05), but youth still manifested appreciable impairment at end-point. CONCLUSIONS: CNS simulants were well tolerated by children with ADHD comorbid with a diagnosis of DMDD. CNS stimulants were associated with clinically significant reductions in externalizing symptoms, along with smaller improvements in mood. However, most participants still exhibited significant impairment, suggesting that additional treatments may be needed to optimize functioning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974 · cited 1×
“In the Multimodal Treatment Study of Children with ADHD (MTA), participants with ADHD, ODD, and internalizing symptoms, as well as those with manic-like symptoms, were most responsive to treatments integrating pharmacological and behavioral modalities (Jensen et al. 2001; Galanter et al. 2005).”
Self-citationGreenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Evidence-Based Assessment of Attention Deficit Hyperactivity Disorder in Children and Adolescents
Pelham, Jr., Fabiano, G. A., & Massetti, G. M. (2005) · Journal of Clinical Child & Adolescent Psychology · doi:10.1207/s15374424jccp3403_5 · Cited by 803 · cited 1×
“Itwasemployedinstead of the longer DBD-RS because briefer measures of externalizing symptoms have been found to promote completion of scheduled assessments (Pelham et al. 2005).”
Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths
Leibenluft, E. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050766 · Cited by 565 · cited 6×
“There is no gold standard measure for either irritability or mood dysregulation that has been found to reliably detect treatment effects (Leibenluft 2011).”
InfluentialInstability of the DSM-IV Subtypes of ADHD From Preschool Through Elementary School
Lahey, B. B., Pelham, W. E., Loney, J., Lee, S. S., & Willcutt, E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.8.896 · Cited by 528
Self-citation(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Blader, J. C., Schooler, N. R., Jensen, P. S., Pliszka, S. R., & Kafantaris, V. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020233 · Cited by 149 · cited 2×
“Data on mood stabilizers in children with nonepisodic irritability are mixed, and tolerability concerns also exist surrounding their use in children (Henry et al. 2003; Blader et al. 2009; Dickstein et al. 2009).”
Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
Dickstein, D. P., Towbin, K. E., Van Der Veen, J. W., Rich, B. A., Brotman, M. A., Knopf, L., Onelio, L., Pine, D. S., & Leibenluft, E. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.044 · Cited by 148
Irritability in pediatric mania and other childhood psychopathology
LEIBENLUFT, E., BLAIR, R. J. R., CHARNEY, D. S., & PINE, D. S. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1301.022 · Cited by 145
Stimulant-Responsive and Stimulant-Refractory Aggressive Behavior Among Children With ADHD
Blader, J. C., Pliszka, S. R., Jensen, P. S., Schooler, N. R., & Kafantaris, V. (2010) · Pediatrics · doi:10.1542/peds.2010-0086 · Cited by 106
LUBKE, G. H., MUTHÉN, B., MOILANEN, I. K., McGOUGH, J. J., LOO, S. K., SWANSON, J. M., YANG, M. H., TAANILA, A., HURTIG, T., JÄRVELIN, M.-R., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815750dd · Cited by 102 · cited 1×
“The combined subtype was required, as it is associated with the highest level of externalizing symptoms as well as with the greatest impairment among ADHD youth (Lahey et al. 2005; Lubke et al. 2007).”
Cited by
Irritability in child and adolescent psychopathology: An integrative review for ICD-11
Evans, S. C., Burke, J. D., Roberts, M. C., Fite, P. J., Lochman, J. E., de la Peña, F. R., & Reed, G. M. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.01.004 · Cited by 186
Waxmonsky, J. G., Waschbusch, D. A., Belin, P., Li, T., Babocsai, L., Humphery, H., Pariseau, M. E., Babinski, D. E., Hoffman, M. T., Haak, J. L., et al. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.12.011 · Cited by 87
Self-citationBaweja, R., Waschbusch, D. A., Pelham, W. E., Pelham, W. E., & Waxmonsky, J. G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.699687 · Cited by 11
“These efficacy results are consistent with the MTA and with studies enrolling youth meeting criteria for DMDD or Severe Mood Dysregulation (6, 18, 22).”
ResultSelf-citation
Metadata
- Authors
- Baweja, R., Belin, P. J., Humphrey, H. H., Babocsai, L., Pariseau, M. E., Waschbusch, D. A., Hoffman, M. T., Akinnusi, O. O., Haak, J. L., Pelham, W. E., & Waxmonsky, J. G.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03
- Volume
- 26
- Issue
- 2
- Pages
- 154-163
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2264532241
- Cited by
- 40
- References
- 13
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.